NCT02122731

Amiloride for Resistant Hypertension

Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Ib Abildgaard Jacobsen · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the antihypertensive effect of amiloride added to triple antihypertensive therapy in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)

Detailed description

The primary objective of this study was to evaluate the antihypertensive effect of amiloride added to triple antihypertensive treatment in patients with resistant hypertension and type 2 diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional study. The secondary objectives were to evaluate the additional effects of amiloride on: * Urinary albumin excretion * Blood pressure control, how many patients reached blood pressure control when amiloride was added to previous triple antihypertensive treatment. * Plasminogen and plasmin excretion (ENaC activity) in the micro-and macroalbuminuric patients in the cohort. * Urokinase plasminogen activator (uPA) activity

Conditions

• Hypertension
• Type 2 Diabetes Mellitus
• Microalbuminuria

Interventions

Type	Name	Description
DRUG	Amiloride	5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.

Timeline

• Start date: 2010-11-01
• Primary completion: 2012-07-01
• Completion: 2012-08-01
• First posted: 2014-04-24
• Last updated: 2014-04-24

Locations

4 sites across 1 country: Denmark